Charles Pillow, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 28.0% of the total.
Across 232 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$832
- GSK$393
- Novo Nordisk$299
- Pfizer$261
- Lilly USA, LLC$235
- plus $927 from 21 others
What the payments were for
- Food & beverage$4,090100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,144 |
| AbbVie | 55 | $832 |
| GSK | 24 | $393 |
| Novo Nordisk | 17 | $299 |
| Pfizer | 17 | $261 |
| Lilly USA, LLC | 16 | $235 |
| Abbott | 10 | $192 |
| Boston Scientific | 2 | $96 |
| Exact Sciences | 6 | $94 |
| Amgen | 4 | $66 |
| Boehringer Ingelheim | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 4 | $55 |
| Merck | 4 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Corium, LLC | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $30 |
| Dexcom, Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Sanofi | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,090 in reported general payments places this provider in the 80th percentile of 133 medical providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 158 | $174,240 |
| JardianceEmpagliflozin | 126 | $110,214 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $50,076 |
| EliquisApixaban | 55 | $47,261 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $40,470 |
| MounjaroTirzepatide | 31 | $39,852 |
| TrulicityDulaglutide | 27 | $36,594 |
| AristadaAripiprazole Lauroxil | 12 | $36,179 |
| FarxigaDapagliflozin Propanediol | 35 | $31,142 |
| VraylarCariprazine Hcl | 16 | $23,272 |
| LinzessLinaclotide | 22 | $21,237 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $21,006 |
| XareltoRivaroxaban | 32 | $20,323 |
| RexultiBrexpiprazole | 12 | $17,361 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $17,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $299 | $174,240158 claims |
| Boehringer IngelheimJardiance | $56 | $110,214126 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,144 | $78,440104 claims |
| Lilly USA, LLCMounjaro, Trulicity | $235 | $76,44558 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $393 | $62,19697 claims |
| PfizerEliquis | $261 | $47,26155 claims |
| AbbVieVraylar, Linzess | $832 | $44,51038 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24 | $17,36112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 133 medical providers in Arkansas.
Other medical in Beebe
- Matthew ReynoldsRussellville$207K
- Tara BrunerSearcy$16K
- Dallas BondhusHot Springs$15K
- Douglas ClarkLittle Rock$14K
- Alexandra SanromaLittle Rock$11K
- Caleb MasonSearcy$9K
- Katherine McCradyLittle Rock$9K
- Bailey PollockLittle Rock$9K
- Hannah BreauLittle Rock$9K
- Thurman SmithFayetteville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.